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photon emission computed tomography; VMAT, vesicular monoamine transporter; GLP1, 
glucagon-like peptide-1; PSA-NCAM, polysialylated neural cell adhesion molecule; RIP-DTr, rat 
insulin promoter diphtheria toxin; SUR 1, sulfonylurea receptor 1; STZ, streptozotocin; T1DM type 
1 diabetes; T2DM, type 2 diabetes; TMEM27, transmembrane protein 27; USPIO, ultrasmall 
superparamagnetic iron oxide 
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Abbreviations,; IMIDIA, Innovative Medicines Initiative in DIAbetes; MRI, magnetic resonance 
imaging; OPT, optical projection tomography; PET, positron emission tomography; SPECT, single 
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Abstract 
Diabetes mellitus is a growing worldwide epidemic disease, currently affecting 1 in 12 adults. 
Treatment of disease complications typically consumes ~10% of healthcare budgets in developed 
societies. Whilst immune-mediated destruction of insulin-secreting pancreatic β-cells is 
responsible for Type 1 diabetes, both the loss and dysfunction of these cells underlies the more 
prevalent Type 2 diabetes. The establishment of robust drug development programmes aiming at 
β-cell restoration is still hampered by the absence of means to measure β-cell mass prospectively 
in vivo, an approach which would provide new opportunities for understanding disease 
mechanisms and ultimately assigning personalized treatments. Here, we describe progress 
towards this goal achieved by the Innovative Medicines Initiative in DIAbetes (IMIDIA), a 
collaborative public-private consortium supported by the European Commission and dedicated 
resources of pharmaceutical companies. We compare several of the available imaging modalities 
and molecular targets and provide suggestions as to the likeliest to lead to tractable approaches. 
Furthermore, we discuss the simultaneous development of animal models that can be used to 
measure subtle changes in β-cell mass, a prerequisite for validating the clinical potential of the 
different imaging tracers. 
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Introduction 
 
Changes in pancreatic β-cell mass contribute to the development of both type 1 (T1DM) and Type 2 
(T2DM) diabetes, diseases which currently affect >340 million individuals worldwide [1] and 
whose incidence in adults is projected to increase by ~20 % by 2030. Whereas immune cell-
mediated mechanisms lead to near-complete (>90%) elimination of β-cells in T1DM, both the 
extent of the loss [estimates range from ~ 25 % [2] to 60 % [3]] and the underlying defect are less 
well established for T2DM [4]. Nonetheless, these changes are likely to involve the interplay of 
genetic and environmental factors.  
 
β-cells comprise only 0.3-2.0 % of the total pancreatic mass [2]. Distinguishing such a rare 
population of cells from others in the pancreas is extremely difficult and, whilst several approaches 
provide information on functional β-cell mass, those quantifying the “absolute” β-cell number or 
volume are less well developed. Moreover, and as already indicated above, there is substantial 
variation in β-cell mass even between healthy subjects [2].  These challenges make it unlikely that 
β-cell mass imaging will be used as a predictive tool for diagnosing diabetes in humans in the near 
future. It is more likely that the value of β-cell mass imaging can be exploited in longitudinal 
studies or clinical trials where two or more time points will indicate increases or decreases in β-cell 
mass in the same individual.  
 
In recent years, there has been significant progress in our understanding of how β-cell mass is 
regulated [5-8] and today drug development is geared towards compounds that can increase β-cell 
mass or prevent β-cell death. While the efficacy of such compounds is relatively easy to determine 
in mice and rats using post mortem histology, it is very challenging to translate these results to 
humans. At present, only measurements of circulating C-peptide and insulin levels may allow β-cell 
mass assessments, and these approaches are indirect, and lack sensitivity and reproducibility. 
Facing the urgent need of developing new sensitive tools that can be applied to human, β-cell 
imaging appears as an obvious candidate. However it should be noted that, given the high 
variability in β-cell mass, which can exceed 100% as typically found in healthy individuals [2], β-
cell imaging may in fact be limited to the longitudinal monitoring of β-cell mass rather than being 
used as a pure diagnostic tool. Yet, the main challenge resides in the detection of subtle changes as 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
opposed to the almost complete loss of β-cell mass as found in people affected by T1DM, and long-
term T2DM, respectively. 
 
For the past four years, the pharmaceutical companies Novartis, Novo Nordisk, Roche, Sanofi and 
Servier have been working together in close collaboration with academia to develop new tools for 
β-cell imaging. Thus, in 2008, the European commission launched the Innovative Medicines 
Initiative (IMI) with the goal of ‘significantly improving the efficiency and effectiveness of the drug 
development process with the long-term aim that the pharmaceutical sector produces more effective 
and safer innovative medicines’ [9-11]. IMIDIA (The Innovative Medicine Initiative in Diabetes; 
[12]) is one of several programmes within IMI and was launched in 2009. Comprising 12 academic 
institutes, 8 pharmaceutical companies and one Biotechnology Company, the overall goal of the 
consortium is to generate new tools, biomarkers and knowledge on β-cell biology and this includes 
imaging pancreatic β-cell mass. Facing the urgent need of developing new sensitive tools that can 
be applied to human, β-cell imaging appears as an obvious candidate. However it should be noted 
that, given the high variability in β-cell mass, which can exceed 100% as typically found in healthy 
individuals [2], β-cell imaging may in fact be limited to the longitudinal monitoring of β-cell mass 
rather than being used as a pure diagnostic tool. Yet, the main challenge resides in the detection of 
subtle changes as opposed to the almost complete loss of BCβ-cell mass as found in T1DM and 
long-term T2DM, respectively 
 
Imaging of β-cells has recently been reviewed in a number of excellent publications [13-17]. 
However, here we further discuss how we envisage that β-cell imaging will enable the development 
of new therapeutics for β-cell regeneration and transplantation, as well as contribute to knowledge 
development around personalized medicine, disease progression, biomarker validation, translational 
applications and drug design. Finally, we provide our vision on β-cell imaging in the future, and 
how we believe this is likely to advance drug discovery. 
 
 
 
Development of Imaging Probes.  
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The process of developing imaging agents for the measurement of β-cell mass in humans can be 
structured into a number of consecutive stages, starting with the identification of a β-cell specific 
target and agent (Fig. 1A, left), and ending with a probe suitable for measuring β-cell mass (Fig. 
1A, right). However, for each step the biological complexity and safety concerns increase and, as a 
consequence, the number of promising agents decreases. In the early stages, there is a need to 
establish at least some β-cell specificity and the cellular resolution offered by a fluorescent tracer is 
attractive. However, for in vivo imaging, other imaging modalities such as magnetic resonance 
imaging (MRI) and positron emission tomography/single photon emission computed tomography 
(PET/SPECT) are likely to be the only realistic options for studies in large animals and in man. 
Within IMIDIA, β-cell imaging is organised in six approaches, which together span all the steps 
considered to be important for the development of a tracer capable of measuring β-cells mass in 
humans (Fig. 1B).  Furthermore, keeping in mind that the overall purpose of this consortium is to 
study drug-induced changes in β-cell mass over time, we are employing various models for β-cell 
regeneration. These include the rat insulin promoter diphtheria toxin (RIP-DTr) mice where 100% 
or 50% of the β-cell mass can be ablated [18, 19] and the insulin antagonist S961 that was recently 
shown to increase β-cell mass [6]. 
 
Imaging modalities 
Among available modalities, MRI provides excellent anatomical resolution but suffers at the 
molecular scale due to its intrinsic low sensitivity: targets are therefore likely to be abundant, and 
their visualization may require high concentrations of tracer. PET imaging, on the other hand, 
provides higher sensitivity but brings challenges of low resolution, high costs and limited 
convenience. At present, computer tomography (CT) and ultrasound provide little specificity. As 
for fluorescence imaging, effective light penetration in the tissue being limited to a few cm, new 
near-infrared fluorescent β-cell imaging agents may only be used for studies in small rodents (i.e. 
mouse). In addition, CT and MRI contrast agents are typically dosed at concentrations in the mM 
range, which can carry a significant toxicological risk. This makes the development process of such 
tracers nearly as long and expensive as for a new therapeutic drug[20]. By contrast, PET 
radiotracers are typically administered in microdoses, which by definition should not elicit a 
pharmacological effect. Thus, under the new guidance from health authorities (ICH guidelines 
[21]), PET tracers may be in a better position to offer a first solution for clinical trials, until another 
generation of tracers, including those developed for use in clinical MRI scanners, become available.  
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Specific criteria for β-cell imaging  
For MRI-based studies, the chief challenge is in identifying target molecules which are both 
abundant and, at least to some extent, selectively accumulated by the β-cell. As described in the 
next section, metal ions such as Zn2+ and Mn2+ ions, as well as sulphonylurea (SUR-1) and 
glucagon-like peptide-1 (GLP-1) receptors provide examples, which might be targeted in useful 
approaches to functional and total β-cell mass assessment, respectively.  
 
For PET studies, the main challenge resides in the selection of a radiolabelled ligand with a 
reasonably high affinity for a β-cell specific target as well as high specific activity. Using a realistic 
number of 100,000 binding sites/cell and assuming a need for a contrast between specific and 
unspecific labelling of at least 5:1, one can estimate that the dissociation constant Kd of such a 
ligand needs to be less than 1 nM [22, 23]. The sensitivity may be greater if the selected tracer uses 
a specific mechanism to accumulate in β-cells. A slow dissociation from the target, fast elimination 
of the free extracellular tracer and low non-specific binding could reduce this requirement for high 
affinity by a factor of ~10.  
 
Other practical aspects include high signal-to-noise ratio, favourable pharmaco-kinetics and absence 
of toxicity. Furthermore, the low spatial resolution of positron cameras prevents distinction of islets 
dispersed within the exocrine pancreas. The resulting partial volume effect can affect to some 
degree quantification of the pharmacological response, unless the β-cell ligand proves to be highly 
specific. Similarly to other tracer developments, acceptance criteria must be met for biological 
qualification (using e.g. tissue autoradiography) prior to costly imaging sessions in animal models 
and/or humans. Kinetic modelling may also be considered for accurate quantification.  Stability in 
the expression of the target (i.e. number of binding sites/β-cell) should preferably be independent of 
disease status. At the stage of research and preclinical development, multimodal probes (e.g. 
combining fluorescent, MRI or even PET-active moieties within the same molecule) may be useful 
to facilitate preclinical studies in model systems including rodents. 
 
Tools and targets for imaging of β-cell mass  
 (1) “Absolute” β-cell mass. The following examples are of targets whose expression is likely to 
reflect the total number (or volume) of β-cells, rather than secretory function.  
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Bioluminescence 
Bioluminescence is the emission of light resulting from the catalysis of luciferin by a luciferase 
enzyme [24, 25]. Using highly sensitive cameras, the few photons emitted by a tissue source can be 
detected at the surface of an animal, making the method adaptable in vivo to many different systems 
[24, 26]. The only requirement is the prior provision of the enzyme substrate, usually by injection, 
to the organism under study. However, a serious limitation is that luciferase needs first to be 
expressed by transgenesis or transduction, possibly in selected cell types, using a cell-specific 
promoter [25]. Using part of the insulin promoter to target luciferase to pancreatic β−cells [27], 
bioluminescence imaging has been documented to provide a signal linearly related to the mass of 
rodent β-cells [27]. Thus, β-cell mass can be rapidly and repeatedly monitored over time in the very 
same animal, e.g. as loss of β−cells is chemically induced [28] or spontaneously develops in models 
of type 1 [29, 30] or type 2 diabetes [31]. In vivo bioluminescence imaging can also monitor the 
fate of islets after transplantation [32, 33], and the regeneration of β-cells exposed to candidate 
drugs [34]. It also significantly contributes to the evaluation of alternative imaging approaches [33].  
 
Findings from IMIDIA  
In collaboration with Powers and colleagues, who pioneered the study of beta cell mass by 
bioluminescence imaging [27, 30, 32, 33], we have studied a transgenic model which provides for a 
differential loss of β-cells in male (> 95 %) and female mice (~ 50%) of the RIP-DTr strain [18].  
Two independent mouse strains expressing both the luciferase and the RIP-DTr transgenes in the 
β−cells were generated [33]. In both strains, the bioluminescence monitoring of the very same mice, 
prior and after injection of a cytotoxic dose of diphteria toxin, showed that the rapid, and almost 
complete loss of β−cells observed in male mice, correlated with a parallel depletion in the insulin 
content of the pancreas [33]. In female mice, the same experiment also showed that the loss of 
about half the β−cells, which correlated with a more modest loss of the insulin content and of the 
bioluminescence imaging signal [33]. The data show that bioluminescence imaging can detect a 
submaximal change of the β-cell mass, with an amplitude similar to that expected in people with 
T2DM, and differentiates this moderate change from the much larger change, which mimics the 
situation prevailing in most type 1 diabetics. We further longitudinally monitored the animals, for 
up to 9 months, and observed that both the insulin content and bioluminescence imaging signal of 
male mice remained at the low levels. In contrast, about 30% of the females showed a progressive 
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and regular increase of the bioluminescence imaging signal (Vinet et al., unpublished). At the end 
of the experiment, the increased bioluminescence imaging signal correlated with a partial recovery 
of the insulin content. The data demonstrate the lack of toxicity of the bioluminescence imaging 
procedure, and show that the approach has the sensitivity to prospectively monitor, in individual 
animals, subtle changes of the β-cell mass.  
 
The findings summarized above stress the versatility of the bioluminescence approach, and its 
relevance in islet and diabetes research. Although the method does not translate to human, it serves 
a purpose in preclinical settings to evaluate potential candidate drugs before the trials on large 
animals and humans. 
 
TMEM27 (antibody) 
Although likely to be challenging, selective targeting and imaging of β−cells using an antibody-
mediated approach is feasible in vivo[35], and may be useful for both preclinical and clinical 
applications. The transmembrane protein 27 (TMEM27) is selectively expressed on the β-cell 
surface and in kidney collecting ducts[36]. A monoclonal antibody, 8/9-mAb is specific to human 
TMEM27 (hTMEM27)[37], and upon suitable labelling, could be used for specific imaging of β-
cells in vivo by fluorescence or PET imaging. The specificity of fluorescently-labelled 8/9-mAb was 
evaluated in human tissue sample microarrays and pancreatic sections from transgenic mice 
expressing hTMEM27 under the control of rat insulin promoter (RIP-hTMEM27-tg). The 
biodistribution of the antibody and its binding to hTMEM27 in vivo were assessed in a nude mouse 
subcutaneous insulinoma model expressing high levels of hTMEM27 using [89Zr]-8/9-mAb, which 
revealed a high signal-to-background contrast in subcutaneous tumours one day after antibody 
injection. In addition, target-specific in vivo imaging was used to assess β-cells in RIP-hTMEM27-
tg mice with fluorescent labelled AF 680–8/9-mAb and similarly high label retention in the 
pancreatic islets of the RIP-hTMEM27-tg mice was observed[37]. 
 
Findings from IMIDIA 
The human TMEM27-specificity of 8/9-mAb limits its use for β-cell in vivo imaging in preclinical 
models of diabetes. Therefore changes in β-cell mass during disease progression or therapeutic 
intervention cannot be assessed with 8/9-mAb in rodent models. Cross species selective antibodies 
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against β−cell specific surface proteins can overcome this hurdle. Further studies need to be 
conducted to monitor changes in β-cell mass in vivo and assess the safety of such approaches. 
 
PSA-NCAM (antibody) 
The polysialylated Neural Cell Adhesion Molecule (PSA-NCAM) is a post-translationally modified 
form of NCAM (CD56) [38]. High expression of PSA-NCAM is found during development, 
specifically in the central nervous system, where it is involved in tissue modeling [39], but after 
birth, PSA-NCAM is mainly restricted to certain brain regions and pancreatic β-cells. The specific 
expression of PSA-NCAM in rodent pancreatic β-cells was shown in 1994 [40], and later confirmed 
[41, 42]. A positive correlation was also demonstrated between PSA-NCAM expression level and 
altered β-cell mass in animal models. However, PSA-NCAM expression at the cell membrane 
correlates with the secretory capacity of β-cell, suggesting that this molecule may also reflect 
functional β-cell mass. 
 
Findings from IMIDIA 
Consistent with its possible use as a marker for β-cell imaging, unpublished data obtained on human 
pancreatic sections indicated that PSA-NCAM is mainly expressed in the endocrine pancreas 
consistent with earlier findings [43]. However, in this study, PSA-NCAM staining performed on 
dispersed pancreatic islet cells was also detected in other (non-β) endocrine cells. Nonetheless, 
magnetic sorting of dispersed cells using PSA-NCAM antibody resulted in an enriched endocrine 
cell population, of which ~95% were β-cells [43]. Specific expression of PSA-NCAM in human β-
cells remains thus to be confirmed. 
 
The potential of PSA-NCAM as a marker for non-invasive imaging of β-cells can be assessed in 
rodents using a labeled PSA NCAM antibody. To determine whether an antibody-based approach to 
target PSA NCAM can be developed for β-cell imaging, biodistribution and toxicity studies will be 
essential. Preliminary data using whole islet isolated from rats indicate that antibody binding to 
PSA NCAM sites on β-cells does not affect glucose-stimulated insulin secretion, demonstrating the 
absence of functional toxicity. However, extended toxicity studies will be needed in both in vitro 
and in vivo models to validate this approach. 
 
GLP-1R (ligand) 
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Peptides targeting the glucagon-like peptide-1 receptor (GLP-1R) are promising candidates for use 
in β-cell imaging because 1) they should target the β-cells with high specificity [44-55], given the 
abundant expression of these receptors on native islet β-cells [56] and 2) they are safe and already 
used in the clinic for treatment of type 2 diabetes. Among these, Exendin-4, found in the saliva of 
the Gila monster [57], binds to the extracellular domain of GLP-1R with pM affinity [58]. Exendin 
derivatives have, therefore, been developed for fluorescence, nuclear and MR imaging of 
endogenous β-cells [47, 53, 59-65], transplanted islets [66, 67] and insulinomas [65, 68-70], 
including in humans [51]. The recent PET and SPECT studies open up the possibility of testing the 
exendin-4 derivatives in a clinical setting. These studies, however, have also revealed the difficulty 
to quantify the low signals emanating from native islets [63, 71]. Such limitations may prevent the 
detection of submaximal changes of β-cell mass, e.g. in the monitoring of early onset T1DM or 
T2DM or potentially their use in regenerative β-cell-targeted therapies. Furthermore, the above 
studies have confirmed the high kidney uptake of the positron-emitting exendin probes [63, 71], 
raising serious safety concerns for use in longitudinal studies where repeated imaging is necessary.  
 
Findings from IMIDIA  
Following intravenous injection, the fluorescently-labelled probes targeted the β-cells in the 
pancreas to a very high extent. At the cellular level, it was possible to determine that the GLP-1R 
agonist, exendin-4 (Ex4), was internalised into the β-cells while the antagonist (Ex4_9-39) 
remained at the plasma membrane. Furthermore, 3D imaging (OPT) revealed that, in the mouse 
pancreas, the probes were highly specific for the β-cell. The signal in the β-cells was completely 
lost in mice lacking the GLP-1R confirming that the accumulation is mediated by this receptor. 
Efforts to characterize the specificity of the probe in various mouse models of diabetes are currently 
ongoing [72]. In parallel, in order to evaluate if MRI can be used to measure β-cell mass, we 
developed a different, dual modality nanoparticle probe, which targets GLP-1R, and is suitable for 
both fluorescence and MRI. The probe (Np647-Ex) consists of multiple copies of a modified 
exendin-4 peptide linked to USPIOs, tagged with Alexa 647 fluorochrome [72]. The probe 
selectively targets insulin-containing cells and allows longitudinal monitoring of individual animals, 
whilst differentiating between partial (~50 %) and almost complete loss of β-cells [18]. 
 
Sulfonylurea receptors (Small molecule) 
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Sulfonylureas are antidiabetes drugs used to mitigate T2DM symptoms by increasing insulin 
secretion. The drugs bind to specific sulfonylurea receptors (SUR 1) located in the plasma 
membrane of pancreatic islet cells [73, 74] but not in the exocrine acinar cells [75]. SUR1s are 
expressed at high density in β-cells [73, 74, 76] but also other endocrine pancreatic cells [75]. 
Despite this, the established clinical use of sulfonylureas, such as glibenclamide [22, 75-77] makes 
these drugs attractive candidates for β-cell mass imaging.  
 
Findings from IMIDIA 
Previous studies have revealed complications in the use of glibenclamide including binding to 
plasma proteins, rapid clearance and insufficient accumulation in the islets [22, 74-76, 78]. We have 
thus tested modified versions of the original molecules carrying moieties detectable by different 
imaging modalities, specifically in vivo fluorescence, which do not excessively disturb the binding 
affinity to SUR1. In vitro studies on living cells showed that several configurations, where multiple 
rhodamine molecules were directly attached to native glibenclamide resulted in probes without 
affinity for SUR1. We therefore decided to use a backbone permitting the attachment of both 
glibenclamide-derivatives (e.g., glib-B) and the rhodamine fluorochromes. 
 
Testing such backbones, we found useful the non-toxic PolyAMidoAMide (PAMAM) dendrimers 
[79, 80] to increase hydrophilicity (thereby decreasing binding to plasma proteins). Spherical probes 
containing 3 to 7 glib-B moieties (Ø~6 nm diameter) displayed the best compromise between 
specificity and affinity and specifically bound to SUR1 of insulin-containing cells in mouse and 
human islets (Babič, Lamprianou et al. in preparation). However, intravenous injection of selected 
probes in control mice resulted in intense staining of vessels in the endocrine pancreas, as well as in 
the glomeruli of the kidney. Moreover, hypoglycaemia was not observed, implying that the probes 
do not bind (or bind only weakly) in vivo to the SUR1 of the insulin-producing cells.  
 
VMAT2 (Small molecule) 
Vesicular monoamine transporter (VMAT) is a transmembrane protein that translocates 
monoamines from the cytoplasm into secretory vesicles. The type 2 protein (VMAT2) is highly 
expressed in pancreatic β-cells [81], and may have a possible role in insulin secretion [82]. PET-
based quantitation of VMAT2 was made possible by the development of radiolabelled 
dihydrotetrabenazine (DTBZ) analogs, which specifically bind to VMAT2. Of the compounds 
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tested within IMIDIA, [18F]FP-(+)-DTBZ (or [18F]AV-133) appears to be the most promising 
candidate tracer, both in rodents and humans [83-86], especially since it was shown in a cross-
sectional study to be able to discriminate people with T1DM from healthy volunteers, despite some 
residual binding (~30% of healthy subjects) in the pancreas [50]. However, the specificity of 
molecules targeting VMAT2 was brought into question when Goland et al. [83] reported significant 
[11C]DTBZ uptake in long-standing type 1 diabetes, in line with Tsao et al. [87] showed low non-
specific binding of [18F]AV-133 to non-β-cells in rats. It recently appeared that non-specific binding 
as estimated by the negative enantiomer [18F]FP-(-)-DTBZ in T1D pancreata, normal human and 
non-human primate pancreas is most likely less than 15% of the total signal [109,110]. This leaves 
the other portion of binding to be off-target (i.e. non β-cells) binding to VMAT2. To which extent 
such residual VMAT2-positive signal also emanates from insulin negative cells, including β-cell 
precursors and polypeptide (PP) cells [82,83] remains to be clarified. Yet, several studies have 
suggested that adult β-cells might originate from duct or duct-associated cells [109,110] and 
VMAT2 was also shown to regulate differentiation in β-cell precursors [111].  Meanwhile, it 
appeared that rodents may not be optimal for DTBZ imaging of β-cells [33, 88], while primates or 
pigs may be better suited to the study of the human disease. 
 
Findings from IMIDIA 
Our efforts were geared towards further validation of the VMAT2 target in a large animal species, 
as well as assessing the usefulness of this target to detect a longitudinal change in β-cell mass in 
vivo. To this end, minipigs were treated with streptozotocin (STZ) to induce β-cell loss. Clear 
uptake of [18F]FP-DTBZ could be visualized from in vivo PET images in the pancreas of 
normoglycemic pigs and quantified by measuring the corresponding standardized uptake value 
(SUV). Individual results appeared to be associated with a ~10% variability as shown from test-
retest measurements, whereas inter-individual variations exceeded 200%, in line with human data. 
A moderate decrease in the pancreatic uptake of [18F]-FP-DTBZ could be visualized in response to 
STZ treatment (unpublished). Whether such a decrease correlates well with β-cell mass as measured 
post-mortem by histology, both with insulin and VMAT2 staining, still needs to be investigated.   
 
(2) “Functional” β-cell mass. The following are examples of targets, which might be used to 
measure absolute or functional β-cell mass. 
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Zinc 
High concentrations of Zn(II) ions exist in insulin granules (ca. around 30 mM) [89] of which a 
small but significant proportion (1-100 μM) is unbound[90]. Zn2+ is also present in alpha cell 
granules, albeit at lower levels [91]. Given the relative scarcity of zinc ions throughout the rest of 
the pancreas [92], and the widespread use of the colorimetric zinc probe dithizone to stain islets, 
imaging agents capable of binding Zn(II) may be useful as a means to quantify β-cell mass in vivo. 
 
There are very few reported MR imaging agents for quantification of β-cell mass that focus on zinc 
binding. One example is GdDOTA-diBPEN, an MR agent sensitive for Zn(II), as reported by 
Lubag and colleagues [93, 94]. This compound shows enhancement in the MR images of mice in 
regions corresponding to the pancreas, and appears to measure zinc co-secreted with insulin into the 
bloodstream. Thus, images of the pancreas were enhanced only after glucose was elevated to a level 
that stimulates insulin secretion whilst the agent did not enhance MR images of the pancreas in 
euglycemic mice or in mice pretreated with STZ. Serial MR images of mice collected during a 
prolonged period of high-fat (60%) feeding showed a dramatic increase in contrast enhancement 
throughout the abdomen, consistent with expansion of the pancreas and a concomitant overall 
increase in β-cell function.  
 
Findings from IMIDIA  
We have recently developed a novel dual-modal MRI/optical probe for zinc [95]. This is based 
around the ‘gold standard’ DOTA motif[96] featuring a Gd(III) centre (MRI) alongside a 
fluorophore which acts as both the fluorescence probe and zinc binding motif. The probe has a Kd 
of 22 µM, and undergoes a ratiometric shift in fluorescence emission from 410 nm to 500 nm, with 
a relaxivity of 4.2 mM-1.s-1. This value increases upon addition of half an equivalent of Zn(II) to 6.6 
mM-1.s-1, decreasing back to 4.9 mM-1.s-1 (at 400 MHz). Cellular imaging data show that this probe 
localises to the β-cell granule, consistent with binding to free zinc in this compartment. In vivo 
studies show limited uptake into the pancreas, consistent with selective uptake into the endocrine 
(β-cell) compartment. The probe is efficiently accumulated into secretory granules in β-cell-derived 
lines and isolated islets, but more poorly by non-endocrine cells, and leads to a reduction in T1 
relaxation in human islets. Biodistribution studies demonstrated clear but low uptake of the agent 
into the pancreas, and suggest that this probe can potentially report either β-cell mass (total zinc-
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positive volume) or function (average intensity per islet) if used in combination with other measures 
of β-cell mass. However, it should be noted that single islet resolution is presently unlikely to be 
achieved with existing clinical scanners (<7 Tesla). 
 
Manganese  
Manganese ions (Mn2+) significantly enhance the contrast of MR images by shortening the T1 
relaxation time and enhances the contrast of the pancreas [97] by entering stimulated β-cells 
through calcium channels[98]. Mn2+ has thus emerged as a potential tool for the in vivo evaluation 
of (functional) β-cell mass. Correspondingly, Mn2+- enhanced MRI (MEMRI) of the pancreas was 
significantly decreased after an almost complete loss of β-cells in a mouse model of chemical 
ablation [99], and progressively declined with the loss of β-cell mass in a model of type 1 diabetes 
[100].  
 
Findings from IMIDIA  
To further evaluate the usefulness of Mn2+ as an MRI contrast agent to monitor the β-cell 
mass/function, we first used a high field (14.1T) MRI machine to assess whether Mn2+ could confer 
a contrast sufficient to visualize native, individual islets [98, 99, 101-103]. In normoglycemic 
conditions as well as after glucose infusion, MEMRI distinguished different tissues within the 
pancreas, including individual islets with a diameter larger than 50 µm, and correctly quantified 
their volume density [103]. MEMRI also detected a significant decrease in the numerical and 
volume density of islets in a model of T1DM [103].  
 
To investigate the possibility that a clinically available MEMRI could be adequate to monitor the 
change in β-cell mass/function in people with T2DM, we retrospectively evaluated a series of 
whole-body MEMRI for normoglycemic participants or people with T2DM [104]. Enhancement 
was significantly lower in the pancreas of diabetic than of normoglycemic participants [104].   
 
Other β-cell imaging agents not explored in IMIDIA 
The scope of IMIDIA was designed according to the probes the different partners included in the 
program. Consequently this meant that a number of agents known to target β-cells were not 
analysed as part of IMIDIA program and therefore not discussed in this review. Below are listed the 
most promising of these agents and their targets. 
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• IC2, a rat monoclonal IgM Ab, which targets sphingomyelin on the β-cell surface [105].  
 
• Single-chain antibodies (SCA), such as SCA-B1 [106]. The target of SCA-B1 is not known 
but was shown specific for β-cells and suitable for MR imaging, after coupling it with 
highly magnetic cobalt nanoparticles [34].  
 
• Less specifically, hydroxy-tryptophan targets the serotonergic innervation, which is present 
in all the endocrine cells of the pancreas [107]. However, in spite of their wide expression, 
this probe appeared to show a correlation between β-cell mass and pancreatic signal in STZ 
treated rats [107] and have been able to differentiate people with T1DM from healthy people 
[108, 109]  Somatostatin receptors were also proposed as a target for imaging probes to 
monitor β-cell mass. Thus, Sako et al. [110] have synthesized a PET probe, 68Ga-DOTA-
octreotide, and shown that its accumulation in the pancreas was reduced in STZ treated rats.  
 
Concluding remarks: clinical and industrial perspective 
The development of a non-invasive read-out of β-cell mass, combined with measurement of β-cell 
function, is expected to provide improvements in both disease management and clinical trial 
assessments. By demonstrating the mode of action of a candidate drug (e.g. a β-cell preserving or 
regenerating agent), a successful β-cell mass marker will help to decrease risk by allowing critical 
decisions earlier in the drug development process.   
 
Of the agents studied in IMIDIA, the VMAT2 and Exendin based PET tracer presently represents 
the most advanced approaches to assess β-cell mass in humans [50, 51]. However, while both 
tracers may be able to detect differences between people suffering from T1DM and healthy controls 
further studies are required to determine if the sensitivity and specificity is good enough detect 
subtle changes over time. GLP1R agonists may also show significant promise for an MRI 
application in mice and may already be worth considering for use in combination with Zn2+ or Mn2+ 
probes to assess β-cell function in preclinical studies.  
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 An important conclusion from this IMIDIA program is that the development of the tracers needs to 
go hand in hand with development of animal models where subtle changes in β-cell mass can be 
induced and subsequently measured in longitudinal studies. Since none of the probes investigated 
are likely to fulfil all criteria for a “perfect” β-cell imaging agent, these models will provide a 
benchmark for the changes in BCM which are actually possible to measure. Furthermore, it is likely 
that imaging of β-cell mass needs to be developed in combination with other biomarkers. If robust 
methods for imaging of β-cell mass can be developed, then they may serve as references for 
circulating biomarkers reflecting changes in β-cell mass. Since these biomarkers should be more 
convenient and inexpensive compared to imaging, they may become key elements of personalized 
medicine. However until then, it is clear that further hurdles need to be overcome in the 
development of a gold-standard imaging method, as well as appropriate animal models before β-cell 
imaging becomes available in the clinic. New imaging tools from which people with diabetes will 
undoubtedly greatly benefit should emerge from the combined efforts of academic and industrial 
organizations, as described here. 
 
Target Probe FL MRI PET/ SPECT Main Challenges Refs 
TMEM27 antiTMEM27 Successfully Attempted Not Attempted 
Successfully 
Attempted 
1) Only recognizes human TMEM27 
2) Reformatting antibody to tracer  [37] 
PSA-NCAM antiPSA Not Attempted Not Attempted Not Attempted 1) Specificity 2) Reformatting antibody to tracer 
 [41, 
42] 
GLP1R Ex4 Successfully Attempted 
Successfully 
Attempted 
Successfully 
Attempted 
1) GLP-1R expression in disease 
models 
 [47, 51, 
72]  
SUR1 Multimerized Glibenclamide 
Successfully 
Attempted Difficult Not Attempted 
2) Exposure time in vivo.  
3) Retention in blood vessels 
 [22, 
74-76, 
78] 
VMAT2 FP-DTBZ Difficult Difficult Successfully Attempted 
1) VMAT2 expression in PP cells 
2) Validity of rodent models unclear  [50] 
Zn Chelators Successfully Attempted 
Successfully 
Attempted Not Attempted 
1) Toxicity 
2) Sensitivity  [93-95] 
Ca2+ Channel Manganese Not Compatible 
Successfully 
Attempted 
Not 
Compatible 
1) Non specific  
2) Safety concern 
 [97, 99, 
103, 
104] 
Insulín gene Luciferase Successfully Attempted 
Not 
Compatible 
Not 
Compatible 
1) Limited to small transgenic 
animals 
 [27, 
30] 
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Table 1: Summary of the different tracers used in IMIDIA and which tracers they have been 
used with to date. Also listed is the main challenge associated with a particular marker.  
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protein coupled receptor located on the surface of the β-cell and can be targeted with exendin4 and 
other GLP-1 analogues. Zinc is highly abundant in the secretory granules of the β-cell, and hence 
represents another potential target for both absolute and functional measures of β-cell mass. 
Manganese enters the β-cell via the calcium channels and enhances the contrast of MR images by 
shortening the T1 relaxation time. 
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